OLMA
Olema Pharmaceuticals, Inc. · Healthcare
Insiders sold $23.8M of Olema Pharmaceuticals, Inc. in the last 12 months and bought none
OLMA over the last year
OLMA after insider buys
3 months after each buy, from the first price a copier could get.
7 buys since 2020 with 3 months of prices.
Every filing
64 insider filings since 2020, newest first
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
Shane William Charles Kovacs · CH. OPERATING, FINANCIAL Offic
David C. Myles · CH. Discov., Non-clin DEV OFF
Cyrus Harmon · Director
Ian T Clark · Director
David C. Myles · CH. Discov., Non-clin DEV OFF
Naseem Zojwalla · Chief Medical Officer
Bain Capital Life Sciences Investors, LLC · 10% owner
G. Walmsley Graham · Director
G. Walmsley Graham · Director
G. Walmsley Graham · Director
Paradigm Biocapital Advisors LP · 10% owner
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
G. Walmsley Graham · Director
Paradigm Biocapital Advisors LP · 10% owner
Cyrus Harmon · Director
Cyrus Harmon · Director
Naseem Zojwalla · Chief Medical Officer
David C. Myles · CH. Discov., Non-clin DEV OFF
Sean Bohen · President and CEO
Shane William Charles Kovacs · CH. OPERATING, FINANCIAL Offic
David C. Myles · CH. Discov., Non-clin DEV OFF
Cyrus Harmon · Director
Cyrus Harmon · Director
David C. Myles · CH. Discov., Non-clin DEV OFF
Bvf Partners L P/il · Director and 10% owner
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
Cyrus Harmon · Director
Kinney Horn · Chief Business Officer
Kinney Horn · Chief Business Officer
David C. Myles · Chief Development Officer
Bvf Partners L P/il · Director and 10% owner
Kinney Horn · Chief Business Officer
Cyrus Harmon · CTO
Sean Bohen · President and CEO
Kinney Horn · Chief Business Officer
Sean Bohen · President and CEO
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.